BACKGROUND: This study aimed to determine if delayed (18)F-fluorodeoxyglucose ((18)FDG) PET/CT imaging improves quantitation of atherosclerotic plaque inflammation. Blood-pool activity can disturb the arterial (18)FDG signal. With time, blood-pool activity declines. Therefore, delayed imaging can potentially improve quantitation of vascular inflammation. METHODS AND RESULTS: 40 subjects were prospectively assessed by dual-time-point PET/CT imaging at approximately 90 and 180 minutes after (18)FDG administration. For both time-points, global uptake of (18)FDG was determined in the carotid arteries and thoracic aorta by calculating the blood-pool corrected maximum standardized uptake value (cSUVMAX). A target-to-background ratio (TBR) was calculated to determine the contrast resolution at 90 and 180 minutes. Furthermore, we assessed whether the acquisition time-point affected the relation between cSUVMAX and the estimated 10-year risk for fatal cardiovascular disease (SCORE %). A significant increase in carotid cSUVMAX (23%, P < .0001), carotid TBR (20%, P < .0001), aortic cSUVMAX (14%, P < .0001), and aortic TBR (20%, P < .0001) was observed with time. At 90 minutes, cSUVMAX did not relate to SCORE %, whereas at 180 minutes significant positive relations were observed between SCORE % and carotid (τ = 0.25, P = .045) and aortic (τ = 0.33, P = .008) cSUVMAX. CONCLUSIONS: Delayed (18)FDG PET/CT imaging at 180 minutes improves quantitation of atherosclerotic plaque inflammation over imaging at 90 minutes. Therefore, the optimal acquisition time-point to assess atherosclerotic plaque inflammation lies beyond the advocated time-point of 90 minutes after (18)FDG administration.
BACKGROUND: This study aimed to determine if delayed (18)F-fluorodeoxyglucose ((18)FDG) PET/CT imaging improves quantitation of atherosclerotic plaque inflammation. Blood-pool activity can disturb the arterial (18)FDG signal. With time, blood-pool activity declines. Therefore, delayed imaging can potentially improve quantitation of vascular inflammation. METHODS AND RESULTS: 40 subjects were prospectively assessed by dual-time-point PET/CT imaging at approximately 90 and 180 minutes after (18)FDG administration. For both time-points, global uptake of (18)FDG was determined in the carotid arteries and thoracic aorta by calculating the blood-pool corrected maximum standardized uptake value (cSUVMAX). A target-to-background ratio (TBR) was calculated to determine the contrast resolution at 90 and 180 minutes. Furthermore, we assessed whether the acquisition time-point affected the relation between cSUVMAX and the estimated 10-year risk for fatal cardiovascular disease (SCORE %). A significant increase in carotid cSUVMAX (23%, P < .0001), carotid TBR (20%, P < .0001), aortic cSUVMAX (14%, P < .0001), and aortic TBR (20%, P < .0001) was observed with time. At 90 minutes, cSUVMAX did not relate to SCORE %, whereas at 180 minutes significant positive relations were observed between SCORE % and carotid (τ = 0.25, P = .045) and aortic (τ = 0.33, P = .008) cSUVMAX. CONCLUSIONS: Delayed (18)FDG PET/CT imaging at 180 minutes improves quantitation of atherosclerotic plaque inflammation over imaging at 90 minutes. Therefore, the optimal acquisition time-point to assess atherosclerotic plaque inflammation lies beyond the advocated time-point of 90 minutes after (18)FDG administration.
Authors: Masato Otsuka; Nico Bruining; Niels C Van Pelt; Nico R Mollet; Jurgen M R Ligthart; Eleni Vourvouri; Ronald Hamers; Peter De Jaegere; William Wijns; Ron T Van Domburg; Gregg W Stone; Susan Veldhof; Stefan Verheye; Dariusz Dudek; Patrick W Serruys; Gabriel P Krestin; Pim J De Feyter Journal: Invest Radiol Date: 2008-05 Impact factor: 6.016
Authors: Eduardo J Folco; Yuri Sheikine; Viviane Z Rocha; Thomas Christen; Eugenia Shvartz; Galina K Sukhova; Marcelo F Di Carli; Peter Libby Journal: J Am Coll Cardiol Date: 2011-08-02 Impact factor: 24.094
Authors: James H F Rudd; Kelly S Myers; Sameer Bansilal; Josef Machac; Ash Rafique; Michael Farkouh; Valentin Fuster; Zahi A Fayad Journal: J Am Coll Cardiol Date: 2007-08-13 Impact factor: 24.094
Authors: Leon J Menezes; Carl W Kotze; Brian F Hutton; Raymondo Endozo; John C Dickson; Ian Cullum; Syed W Yusuf; Peter J Ell; Ashley M Groves Journal: J Nucl Med Date: 2009-05-14 Impact factor: 10.057
Authors: Axel Rominger; Tobias Saam; Sarah Wolpers; Clemens C Cyran; Michael Schmidt; Stefan Foerster; Konstantin Nikolaou; Maximilian F Reiser; Peter Bartenstein; Marcus Hacker Journal: J Nucl Med Date: 2009-09-16 Impact factor: 10.057
Authors: James H F Rudd; Kelly S Myers; Sameer Bansilal; Josef Machac; Cathy Anne Pinto; Christopher Tong; Ash Rafique; Richard Hargeaves; Michael Farkouh; Valentin Fuster; Zahi A Fayad Journal: J Nucl Med Date: 2008-05-15 Impact factor: 10.057
Authors: J H F Rudd; E A Warburton; T D Fryer; H A Jones; J C Clark; N Antoun; P Johnström; A P Davenport; P J Kirkpatrick; B N Arch; J D Pickard; P L Weissberg Journal: Circulation Date: 2002-06-11 Impact factor: 29.690
Authors: Austin J Borja; Emily C Hancin; Alexandra D Dreyfuss; Vincent Zhang; Toby Mathew; Chaitanya Rojulpote; Thomas J Werner; Shivaraj Patil; Karthik Gonuguntla; Alexander Lin; Steven J Feigenberg; Samuel Swisher-McClure; Abass Alavi; Mona-Elisabeth Revheim Journal: Am J Nucl Med Mol Imaging Date: 2020-02-25